{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T19:32:37Z","timestamp":1777663957566,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"am","delay-in-days":380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.urolonc.2022.10.033","type":"journal-article","created":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T15:31:20Z","timestamp":1671723080000},"page":"254.e9-254.e15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Detection and resection of carcinoma in situ of the bladder: Implications for clinical trial design"],"prefix":"10.1016","volume":"41","author":[{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Belanger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter C.","family":"Black","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2022.10.033_bib0001","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/0008-5472.CAN-20-2336","article-title":"Bladder tumor subtype commitment occurs in carcinoma in situ driven by key signaling pathways including ECM remodeling","volume":"81","author":"Wullweber","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0002","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00345-019-02738-2","article-title":"Concomitant carcinoma in situ may not be a prognostic factor for patients with bladder cancer following radical cystectomy: A PRISMA-compliant systematic review and meta-analysis","volume":"38","author":"Zhang","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0003","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","article-title":"Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: A meta-analysis of detection and recurrence based on raw data","volume":"64","author":"Burger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0004","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2014.10.040","article-title":"Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: A systematic review","volume":"67","author":"Casey","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0005","series-title":"Phase II\/III clinical results of IL-15R\u03b1Fc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients","author":"Chamie","year":"2021"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: A single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0007","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2021.39.15_suppl.4541","article-title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816)","volume":"39","author":"Black","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0008","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0009","unstructured":"BCG-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biologics for Treatment Guidance for Industry.https:\/\/www.fda.gov\/media\/101468\/download. In: (CBER) USDoHaHSFaDACfDEaRCCfBEaR, editor. 2018. access date 2018."},{"key":"10.1016\/j.urolonc.2022.10.033_bib0010","series-title":"Edn presented at the EAU Annual Congress Milan","article-title":"Non-muscle-invasive bladder cancer EAU guidelines","author":"Babjuk","year":"2021"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0011","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0012","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/s41379-019-0403-9","article-title":"Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: Recommendations from the International Collaboration on Cancer Reporting (ICCR)","volume":"33","author":"Varma","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0013","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.juro.2017.11.096","article-title":"Efficacy and safety of blue light flexible cystoscopy with Hexaminolevulinate in the surveillance of bladder cancer: A phase III, comparative, multicenter study","volume":"199","author":"Daneshmand","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0014","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.urolonc.2010.09.009","article-title":"Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder","volume":"30","author":"Lerner","year":"2012","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0015","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/JU.0000000000002308","article-title":"Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Gu\u00e9rin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons","volume":"207","author":"Chappidi","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0016","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.euf.2021.09.025","article-title":"Underutilization of blue light cystoscopy for bladder cancer in the United States","volume":"8","author":"Lewicki","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0017","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.juro.2012.05.015","article-title":"The value of transurethral bladder biopsy after intravesical bacillus Calmette-Guerin instillation therapy for nonmuscle invasive bladder cancer: A retrospective, single center study and cumulative analysis of the literature","volume":"188","author":"Swietek","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2022.10.033_bib0018","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): An open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922004318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143922004318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:27:35Z","timestamp":1761042455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143922004318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1078143922004318"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.033","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection and resection of carcinoma in situ of the bladder: Implications for clinical trial design","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2022.10.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}